Liquid Biopsy Markets by Cancer and Usage Type with Price and Volume Outlook, Includes Impact of COVID-19 with Executive and Consultant Guides 2022 to 2026
“Liquid Biopsy enters exponential growth phase as pandemic subsides”
This latest edition includes revenues, volume and price forecasts to 2026 across the following:
- Cancer type
- Other (can be broken down for specific cancer types on request)
- Usage type
- Screening / early detection
- Therapy selection
- Recurrance monitoring
- Rest of Europe (breakouts available)
- South Korea
- Rest of APAC (breakouts available)
- Rest of Latin America (breakouts available)
- Middle East and Africa (breakouts available)
What has been the impact of the COVID-19 pandemic on the liquid biopsy market so far and how long is it likely to last?
Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls, understand growth expectations and the ultimate potential market size.
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test.
GRAIL, a company with impressive backing, has announced a single blood test to detect all cancers. The company is working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures
The report forecasts the market size out to 2026 and looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring. This huge screening market opportunity is explored by country with an astounding result for the Global potential market size.
The market is still in its infancy but has moved out of development phase and into growth phase.
Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Check all your licensing options however your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with each corporate license as standard.
All report data is available in Excel format on request with the corporate license.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell is a member of The American Association for Clinical Chemistry. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School